EP26
EP26 is a potent and orally active EGFR and PD-L1 inhibitor with IC50 values of 48.6 nM, 1.77 µM, respectively. EP26 decreased the protein expression of p-EGFR. EP26 induces cell cycle arrest at G0/G1 phase. EP26 has the potential for the research of glioblastoma[1].
Product Specifications
UNSPSC
12352005
Target
EGFR; PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ep26.html
Smiles
COC1=CC(OCC2=C(C)C(C3=CC=CC=C3)=CC=C2)=CC(OC)=C1CNCCCCOC4=C(OC)C=C(N=CN=C5NC6=CC=CC(Cl)=C6F)C5=C4
Molecular Formula
C42H42ClFN4O5
Molecular Weight
737.26
References & Citations
[1]Yang Z, et al. Discovery of Novel Small-Molecule-Based Potential PD-L1/EGFR Dual Inhibitors with High Druggability for Glioblastoma Immunotherapy. J Med Chem. 2024 May 23;67 (10) :7995-8019.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
EGFR/ErbB1/HER1
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![ZNF8 Mouse Monoclonal Antibody [Clone ID: OTI2B6]](https://cdn.genprice.uk/products/937/68dd18bb061270361e908c70/imageurl/cf811985.webp)
BNUM2284-50 1x 50 µL
Human IgG4 (Ig Heavy Constant Gamma 4) (G4m Marker) (rIGHG4/1345), 1mg/mL
Sign In for Pricing
View Details